Thomas B. Connor, MD

Publications

• Human iPSC-derived photoreceptor transplantation in the cone dominant 13-lined ground squirrel.

  (Yu CT, Kandoi S, Periasamy R, Reddy LVK, Follett HM, Summerfelt P, Martinez C, Guillaume C, Bowie O, Connor TB, Lipinski DM, Allen KP, Merriman DK, Carroll J, Lamba DA.) Stem Cell Reports. 2024 Mar 12;19(3):331-342 PMID: 38335965 PMCID: PMC10937153 SCOPUS ID: 2-s2.0-85186065745 02/10/2024

• Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.

  (Mahaling B, Low SWY, Ch S, Addi UR, Ahmad B, Connor TB, Mohan RR, Biswas S, Chaurasia SS.) Pharmaceutics. 2023 Jul 22;15(7) PMID: 37514191 PMCID: PMC10383092 SCOPUS ID: 2-s2.0-85166338712 07/29/2023

• Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.

  (Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, SCORE2 Investigator Group.) Am J Ophthalmol. 2022 Aug;240:330-341 PMID: 35461831 PMCID: PMC11064059 04/25/2022

• Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.

  (Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W, AREDS2 Research Group.) JAMA Ophthalmol. 2022 Jul 01;140(7):692-698 PMID: 35653117 PMCID: PMC9164119 06/03/2022

• Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.

  (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Study Investigator Group.) JAMA Ophthalmol. 2022 May 01;140(5):458-464 PMID: 35323843 PMCID: PMC8949717 03/25/2022

• SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.

  (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Investigator Group.) Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1491-1500 PMID: 34842984 PMCID: PMC10887424 11/30/2021

• Long-term retinal imaging of a case of suspected congenital rubella infection

  (Langlo CS, Trotter A, Reddi HV, Schilter KF, Tyler RC, Udani R, Neitz M, Carroll J, Connor TB.) American Journal of Ophthalmology Case Reports. March 2022;25 SCOPUS ID: 2-s2.0-85121217327 03/01/2022

• Damage-Associated Molecular Patterns (DAMPs) in Retinal Disorders

  (Mahaling B, Low SWY, Beck M, Kumar D, Ahmed S, Connor TB, Ahmad B, Chaurasia SS.) International Journal of Molecular Sciences. March-1 2022;23(5) SCOPUS ID: 2-s2.0-85125395177 03/01/2022

• Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.

  (Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK, DRCR Retina Network.) JAMA Ophthalmol. 2021 Dec 01;139(12):1266-1273 PMID: 34673898 PMCID: PMC8532036 10/22/2021

• Development of a Preclinical Laser Speckle Contrast Imaging Instrument for Assessing Systemic and Retinal Vascular Function in Small Rodents.

  (Patel DD, Dhalla AH, Viehland C, Connor TB, Lipinski DM.) Transl Vis Sci Technol. 2021 Aug 02;10(9):19 PMID: 34403474 PMCID: PMC8374978 SCOPUS ID: 2-s2.0-85114392221 08/18/2021

• Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.

  (Khurana RN, Oden NL, VanVeldhuisen PC, Scott IU, Blodi BA, Ip MS, SCORE2 Investigator Group.) Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):1839-1851 PMID: 33415354 PMCID: PMC8260624 01/09/2021

• Small leucine-rich proteoglycans (Slrps) in the retina

  (Low SWY, Connor TB, Kassem IS, Costakos DM, Chaurasia SS.) International Journal of Molecular Sciences. 2 July 2021;22(14) SCOPUS ID: 2-s2.0-85109111419 07/02/2021